MedPath

Dynamic Critical Congenital Heart Screening With Addition of Perfusion Measurements

Not Applicable
Recruiting
Conditions
Congenital Heart Disease
Interventions
Diagnostic Test: SpO2/PIx Measurement and ML Algorithm
Registration Number
NCT05637814
Lead Sponsor
University of California, Davis
Brief Summary

The purpose of this study is to implement and externally validate an inpatient ML algorithm that combines pulse oximetry features for critical congenital heart disease (CCHD) screening.

Detailed Description

The study will externally validate an algorithm that combines non-invasive oxygenation and perfusion measurements as a screening tool for CCHD. In a previous study, the investigators created an algorithm that combines non-invasive measurements of oxygenation and perfusion over at least two measurements using machine learning (ML) techniques. The prior model was created and tested using internal validation (k-fold validation). Thus, the investigators will test the model on an external sample of patients to test generalizability of the model. Additionally, the team will trial a repeated measurement for any "failure" of the screen to assess impact on the false positive rate. Study team will also use repeated pulse oximetry measurements (up to 4 total and including measurements after 48 hours of age, which may be done outpatient) to create a new algorithm that incorporates new data over time. The central hypothesis is that the addition of non-invasive perfusion measurements will be superior to SpO2-alone screening for CCHD detection and a model that incorporates repeated measurements will enhance detection of CCHD while preserving the specificity.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  • Age < 22 days
  • Fetuses suspected to have congenital heart disease
  • Newborns with suspected/confirmed critical congenital heart disease
  • Asymptomatic newborn undergoing SpO2 screening for CCHD
Exclusion Criteria
  • Echocardiogram completed prior to enrollment as the newborn would then no longer be considered "asymptomatic undergoing SpO2 screening for CCHD"
  • For Newborns with confirmed/suspected congenital heart disease (CHD): a) Patent ductus arteriosus and/or atrial septal defect/patent foramen ovale without other defects, b) Corrective cardiac surgical or catheter intervention performed before enrollment or c) Current infusions of vasoactive medications other than prostaglandin therapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
SpO2 and PIx MeasurementSpO2/PIx Measurement and ML AlgorithmNon-invasive measurements of oxygenation (SpO2) and perfusion (PIx) will be measured with pulse oximeters and a ML CCHD screening algorithm will be assigning a prediction every minute.
Primary Outcome Measures
NameTimeMethod
Area under the curve for receiver operating characteristics for critical congenital heart disease using ML inpatient algorithm.Through study completion, an average of 4 years

Receiver operating characteristics reflect a combination of sensitivity and specificity of a test. The investigators will identify the true positive and true negative rates for CCHD by confirming health status to a minimum of 2 months of age. The investigators will also utilize birth defect and death registries for missing infants.

Secondary Outcome Measures
NameTimeMethod
Specificity for critical congenital heart disease using ML inpatient algorithm (0-24 hours and 24-48 hours)Through study completion, an average of 4 years

The investigators will identify the true negative rate by confirming health status to a minimum of 2 months of age. CCHD will be defined based on echocardiogram or parent report if echocardiogram not present. The investigators will also utilize birth defect and death registries for missing infants.

Sensitivity for critical congenital heart disease using ML inpatient algorithm (0-24 hours and 24-48 hours)Through study completion, an average of 4 years

The investigators will identify the true positive rate for CCHD by confirming health status to a minimum of 2 months of age. CCHD will be defined based on echocardiogram or parent report if echocardiogram not present. The investigators will also utilize birth defect and death registries for missing infants.

Sensitivity for critical congenital heart disease using dynamic ML algorithmThrough study completion, an average of 4 years

The investigators will identify the true positive rate for CCHD by confirming health status to a minimum of 2 months of age. CCHD will be defined based on echocardiogram or parent report if echocardiogram not present. The investigators will also utilize birth defect and death registries for missing infants.

Area under the curve for receiver operating characteristics for critical congenital heart disease using dynamic ML algorithmThrough study completion, an average of 4 years

Receiver operating characteristics reflect a combination of sensitivity and specificity of a test. The investigators will identify the true positive and true negative rates for CCHD by confirming health status to a minimum of 2 months of age. The investigators will also utilize birth defect and death registries for missing infants.

Specificity for critical congenital heart disease using dynamic ML modelThrough study completion, an average of 4 years

The investigators will identify the true negative rate by confirming health status to a minimum of 2 months of age. CCHD will be defined based on echocardiogram or parent report if echocardiogram not present. The investigators will also utilize birth defect and death registries for missing infants.

Sensitivity for critical coarctation of the aorta using dynamic ML algorithmThrough study completion, an average of 4 years

Critical coarctation of the aorta is the most commonly missed CCHD. The investigators will identify the true positive rate by confirming health status to a minimum of 2 months of age. The investigators will also utilize birth defect and death registries for missing infants.

Trial Locations

Locations (3)

UC Davis Medical Center

🇺🇸

Davis, California, United States

Cohen Children's Medical Center

🇺🇸

Queens, New York, United States

University of Utah Health Care

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath